Forte Biosciences, Inc.

NasdaqCM:FBRX Voorraadrapport

Marktkapitalisatie: US$6.1m

Forte Biosciences Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Forte Biosciences's earnings have been declining at an average annual rate of -2.4%, while the Biotechs industry saw earnings growing at 19% annually.

Belangrijke informatie

-2.4%

Groei van de winst

60.5%

Groei van de winst per aandeel

Biotechs Groei van de industrie17.0%
Inkomstengroein/a
Rendement op eigen vermogen-210.8%
Nettomargen/a
Laatste winstupdate30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

We're A Little Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate

Jul 17
We're A Little Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate

Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?

Mar 14
Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?

Large Forte Biosciences shareholder scolds company board of directors

Aug 24

We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely

Aug 17
We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely

Forte Biosciences: Lots Of Clinical Risk Ahead And A Questionable Business Plan

Aug 16

Forte Biosciences large shareholders make demands for company's future

Jul 07

We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully

Dec 23
We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully

Forte Biosciences files for $300M mixed shelf offering

May 28

Are Insiders Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Stock?

Mar 13
Are Insiders Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Stock?

Do Institutions Own Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Jan 19
Do Institutions Own Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Forte Biosciences: FB-401 Potentially Best-In-Class In Atopic Dermatitis

Dec 18

Who Has Been Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Nov 25
Who Has Been Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Forte Biosciences readies equity offering

Oct 28

Opbrengsten en kosten

Hoe Forte Biosciences geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

NasdaqCM:FBRX Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 240-361720
31 Mar 240-321221
31 Dec 230-311122
30 Sep 230-301021
30 Jun 230-24816
31 Mar 230-18910
31 Dec 220-1486
30 Sep 220-1284
30 Jun 220-1789
31 Mar 220-19811
31 Dec 210-22814
30 Sep 210-23716
30 Jun 210-20614
31 Mar 210-49512
31 Dec 200-46410
30 Sep 200-4338
30 Jun 200-3925
31 Mar 200-523
31 Dec 190-413

Kwaliteitswinsten: FBRX is currently unprofitable.

Groeiende winstmarge: FBRX is currently unprofitable.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: FBRX is unprofitable, and losses have increased over the past 5 years at a rate of 2.4% per year.

Versnelling van de groei: Unable to compare FBRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: FBRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Rendement op eigen vermogen

Hoge ROE: FBRX has a negative Return on Equity (-210.82%), as it is currently unprofitable.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden